中國醫療集團(08225.HK)為漸凍人募捐義診 幫助基層醫療建立診斷和醫院臨牀研究
格隆匯6月23日丨中國醫療集團(08225.HK)發佈公吿,2021年6月21日是第22個世界漸凍人日,集團組織全國冰桶挑戰賽,發起漸凍人募捐,中國ALS大醫生熱選,幫助基層醫療建立診斷,啟動臨牀研究。冰桶挑戰賽”(ice bucket challenge)是幫助社會認知、關愛漸凍病人以及為他們募捐的活動。肌萎縮側索硬化(ALS)也叫運動神經元病(MND),被稱為超過癌症的五大絕症之一。根據美國的統計,漸凍症患病率約0.357%,以此推算,我國大約有450萬漸凍人,超過500億市場。
集團通過設立在博鰲醫療先行區的喜恩腦科學研究基地,通過大資料深度挖掘,採用真實世界臨牀研究的方法,重新篩選和組合現有藥品,尋找漸凍症最佳治療的萬全之策。中國第一個漸凍人用藥萬全力太(利魯唑片)為集團臨牀研究成果。
管理層認為由於集團在漸凍症臨牀研究在這一治療領域中的領先地位,以及集團旗下“RWS研究中心”大資料和數位化推動的商業活動和基層醫療專業推廣在幫助患者同時將會為集團獲取相當經濟效益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.